Sanofi finishes Genzyme deal, weighs name change

Having wrapped up its acquisition of Genzyme with 84.6 percent of stock tendered, Sanofi-Aventis says the contingent value rights associated with the deal will begin trading--and that it's considering changing its name simply to "Sanofi," to make it easier to pronounce in international markets. Report | Report

Suggested Articles

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.

A patent decision in Delaware clears the way for multiple generic companies to launch their Tecfidera copycats—and target its $3.3B in U.S. sales.

Sanofi and GlaxoSmithKline signed a deal with the EU to supply up to 300 million doses of their recombinant protein-based COVID-19 vaccine.